Evidence map›Paper›PMID 33726628›Full record

ReviewAutophagy2022

TEX264 at the intersection of autophagy and DNA repair.

John Fielden, Marta Popović, Kristijan Ramadan

Open access · bronzeAbstract readReview
In one paragraph

Review in Autophagy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

John FieldenMedical Research Council (MRC) Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0002-9068-1844
Marta PopovićLaboratory for Molecular Ecotoxicology, Division for Marine and Environmental Research, Ruđer Bošković Institute, Zagreb, Croatia.ORCID 0000-0002-9464-5824
Kristijan RamadanMedical Research Council (MRC) Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0001-5522-021X
University of Oxford · GBRuđer Bošković Institute · HR

Funding

Medical Research Council MC_PC_12001/1Medical Research Council MC_UU_00001/1
6 · The paper itself

Abstract

TEX264 (testes expressed gene 264) is a single-pass transmembrane protein, consisting of an N-terminal hydrophobic region, a gyrase inhibitory (GyrI)-like domain, and a loosely structured C terminus. TEX264 was first identified as an endoplasmic reticulum (ER)-resident Atg8-family-binding protein that mediates the degradation of portions of the ER during starvation (i.e., reticulophagy). More recently, TEX264 was identified as a cofactor of VCP/p97 ATPase that promotes the repair of covalently trapped TOP1 (DNA topoisomerase 1)-DNA crosslinks. This review summarizes the current knowledge of TEX264 as a protein with roles in both autophagy and DNA repair and provides an evolutionary and structural analysis of GyrI proteins. Based on our phylogenetic analysis, we provide evidence that TEX264 is a member of a large superfamily of GyrI-like proteins that evolved in bacteria and are present in metazoans, including invertebrates and chordates.

Indexed as

AutophagyEndoplasmic Reticulum StressAutophagy-Related Protein 8 FamilyDNADNA RepairPhylogenyUbiquitinAutophagy-Related Protein 8 FamilyDNAUbiquitinAutophagyDNA repairgyrase inhibitory-like proteinsnucleophagyreticulophagyTEX264

Identifiers

PMID33726628
PMCPMC8865260
OpenAlexW3136704076

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.